Sophiris to Begin Dosing Patients in Phase 2b Study of Topsalysin for Prostate Cancer

Sophiris Bio has received a green light to begin dosing patients in a Phase 2b U.S. clinical trial of topsalysin (PRX302) for prostate cancer. The go-ahead was in the form of a Federal Drug Administration approval of a substance that Sophiris uses to dilute topsalysin, according to a press release. The therapy is for an enlarged prostate as well